MA
HELP

MYDA Advisors’s Helus Pharma Inc. Common Stock HELP Stock Holding History

MYDA Advisors’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,000
Closed -$245K – 166
2025
Q4 		$245K Buy
+30,000
New +$193K 0.05% 126

Other funds holding HELP

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

MYDA Advisors's HELP Position: Q1 2026 in Review

MYDA Advisors sold out of Helus Pharma Inc. Common Stock (HELP) in Q1 2026, closing a stake of 30,000 shares — an estimated $245K sold.

MYDA Advisors first reported a position in HELP in Q4 2025 and held it in 1 quarter. The position peaked at $245K in Q4 2025. 81 funds tracked by Wall St. Rank hold HELP as of Q1 2026.

  • MYDA Advisors reported no remaining Helus Pharma Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • MYDA Advisors sold 30,000 Helus Pharma Inc. Common Stock shares in Q1 2026, an estimated $245K.
  • MYDA Advisors first reported a position in Helus Pharma Inc. Common Stock in Q4 2025 and held it in 1 quarter.
  • MYDA Advisors's Helus Pharma Inc. Common Stock position peaked at $245K in Q4 2025.
  • 81 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q1 2026.

Based on MYDA Advisors's 13F filing for Q1 2026, filed 14 May 2026.